ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 01541) issued a monthly return on movements in its securities for February 2026, confirming no changes in its share capital during the period. The total registered share capital remained at RMB 431.51 million, comprising 420.48 million H shares listed on the Hong Kong Stock Exchange and 11.03 million unlisted shares, each with a par value of RMB 1.

The company confirmed compliance with the minimum public float requirement for its H shares, maintaining the necessary threshold as prescribed by relevant listing rules. No share options, warrants, convertibles, treasury shares, or other arrangements were reported.